Phase II trial of eribulin in patients who do not achieve pathologic complete response (pCR) following neoadjuvant chemotherapy
ConclusionAdministration of adjuvant eribulin after neoadjuvant chemotherapy was feasible and well tolerated. The 24-month DFS rate did not reach the study target levels in any of the cohorts and was similar to DFS previously described in these cohorts following neoadjuvant chemotherapy alone.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
More News: Brain | Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | HER2 | Herceptin | Hormonal Therapy | Hormones | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Neurology | Study